Study on Olanzapine Long-Acting Injection for Schizophrenia
Author Information
Author(s): Angela L. Hill, Bin Sun, Jamie L. Karagianis, Susan B. Watson, David P. McDonnell
Primary Institution: Lilly Research Laboratories, Eli Lilly and Company
Hypothesis
Significant dose-associated changes would be identified for both safety and efficacy parameters in this olanzapine LAI clinical trial.
Conclusion
Higher doses of olanzapine LAI may lead to better efficacy outcomes but also greater adverse changes in metabolic safety measures.
Supporting Evidence
- Higher doses of olanzapine LAI were associated with a lower relapse rate.
- Patients on the high dose had a longer time to relapse compared to those on the low dose.
- Weight gain increased with higher doses of olanzapine LAI.
Takeaway
This study looked at how different doses of a medication for schizophrenia affect patients' health and safety. Higher doses helped more with symptoms but also caused more weight gain.
Methodology
Patients with schizophrenia were randomly assigned to low, medium, or high doses of olanzapine LAI for 24 weeks, and various safety and efficacy measures were analyzed.
Potential Biases
Potential for false positives due to not correcting for multiple comparisons.
Limitations
The analyses were post hoc and exploratory, and certain adverse events during the lead-in phase were not represented.
Participant Demographics
Patients aged 18 to 75 with a diagnosis of schizophrenia.
Statistical Information
P-Value
p <.01
Confidence Interval
95% CI: 4 to 43
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website